MBA MD - Sigilon Therapeutics CEO Pres
Insider
MBA MD is CEO Pres of Sigilon Therapeutics
| Age | 58 |
| Phone | 617 336 7540 |
| Web | https://www.sigilon.com |
Sigilon Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2365) % which means that it has lost $0.2365 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7631) %, meaning that it created substantial loss on money invested by shareholders. Sigilon Therapeutics' management efficiency ratios could be used to measure how well Sigilon Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Sigilon Therapeutics currently holds 28.06 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Sigilon Therapeutics has a current ratio of 2.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Sigilon Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 53 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 60 | |
| Jeffrey Welch | GeoVax Labs | N/A | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 36 | |
| Michael PEng | InMed Pharmaceuticals | 56 | |
| Karen Cashmere | ZyVersa Therapeutics | 73 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Colin Clancy | InMed Pharmaceuticals | N/A | |
| McKee MD | GeoVax Labs | 72 | |
| Swan Sit | NovaBay Pharmaceuticals | 41 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Keith MD | X4 Pharmaceuticals | 54 | |
| Arthur Taveras | X4 Pharmaceuticals | 61 | |
| MPA MD | Unicycive Therapeutics | 52 | |
| Mark Newman | GeoVax Labs | 70 | |
| CPA CPA | GeoVax Labs | 62 | |
| Wang Xu | NovaBay Pharmaceuticals | 36 | |
| John CPA | Unicycive Therapeutics | 63 | |
| Ado Muhammad | InMed Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.76 | |||
| Return On Asset | -0.24 |
Sigilon Therapeutics Leadership Team
Elected by the shareholders, the Sigilon Therapeutics' board of directors comprises two types of representatives: Sigilon Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sigilon. The board's role is to monitor Sigilon Therapeutics' management team and ensure that shareholders' interests are well served. Sigilon Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sigilon Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philip AshtonRickardt, Chief Officer | ||
| MD MBA, Ex Officer | ||
| Arturo Vegas, CoFounder | ||
| Omid Veiseh, CoFounder | ||
| Daniel Anderson, CoFounder Board | ||
| MBA MD, CEO Pres | ||
| Jos MD, CoFounder | ||
| JD Windsor, VP Relations | ||
| Josias MBA, VP, CFO |
Sigilon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sigilon Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (1.71) % | |||
| Operating Margin | (1.75) % | |||
| Current Valuation | 28.99 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 8.69 % | |||
| Shares Owned By Institutions | 54.33 % | |||
| Number Of Shares Shorted | 8.23 K | |||
| Price To Book | 0.25 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Sigilon Stock
If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stocks Directory Find actively traded stocks across global markets |